Suppr超能文献

一种95 kDa高亲和力人高密度脂蛋白结合蛋白的特性鉴定。

Characterization of a 95 kDa high affinity human high density lipoprotein-binding protein.

作者信息

Bocharov A V, Vishnyakova T G, Baranova I N, Patterson A P, Eggerman T L

机构信息

Center for Biologics Evaluation and Research, Division of Cellular and Gene Therapy, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland 20892, USA.

出版信息

Biochemistry. 2001 Apr 10;40(14):4407-16. doi: 10.1021/bi001503k.

Abstract

A new human 95 kDa high density lipoprotein (HDL)-binding protein (HBP) corresponding to a high affinity HDL-binding site with K(d) = 1.67 microg/mL and a capacity of 13.4 ng/mg was identified in human fetal hepatocytes. The HDL binding with the 95 kDa HBP plateaus at 2.5-5 microg/mL under reducing and nonreducing conditions. The association of HDL(3) with the 95 kDa HBP plateaued in 15-30 min while dissociation was complete in 30 min. HDL(3), apoA-I, and apoA-II were recognized by the 95 kDa HBP while low density lipoproteins (LDL) and tetranitromethane-modified HDL were not. The 95 kDa HBP predominantly resides on the surface of cells since trypsin treatment of HepG2 cells eliminated nearly 70% of HDL binding. All studied human cells and cell lines (HepG2, Caco-2, HeLa, fibroblasts, SKOV-3, PA-I) demonstrated the presence of the 95 kDa protein. Both RT-PCR and Western blotting for HB-2/ALCAM were negative in human fetal hepatocytes while Gp96/GRP94 was clearly differentiated from the 95 kDa HBP by two-dimensional electrophoretic mobility. Moreover, deglycosylation of HepG2 membrane preparations did not affect either HDL binding to the 95 kDa HBP or its size, while in contrast it affected the molecular weights of HB-2/ALCAM and SR-BI/CLA-1. We conclude that the 95 kDa HBP is a new HDL receptor candidate widely expressed in human cells and cell lines.

摘要

在人胎儿肝细胞中鉴定出一种新的人95 kDa高密度脂蛋白(HDL)结合蛋白(HBP),其对应一个高亲和力HDL结合位点,解离常数K(d)=1.67 μg/mL,结合容量为13.4 ng/mg。在还原和非还原条件下,HDL与95 kDa HBP的结合在2.5 - 5 μg/mL时达到平台期。HDL(3)与95 kDa HBP的结合在15 - 30分钟内达到平台期,而解离在30分钟内完成。95 kDa HBP可识别HDL(3)、载脂蛋白A-I和载脂蛋白A-II,而低密度脂蛋白(LDL)和四硝基甲烷修饰的HDL则不能被识别。95 kDa HBP主要位于细胞表面,因为用胰蛋白酶处理HepG2细胞可消除近70%的HDL结合。所有研究的人类细胞和细胞系(HepG2、Caco-2、HeLa、成纤维细胞、SKOV-3、PA-I)均显示存在95 kDa蛋白。人胎儿肝细胞中HB-2/ALCAM的逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹均为阴性,而通过二维电泳迁移率可清楚地将糖蛋白96/葡萄糖调节蛋白94(Gp96/GRP94)与95 kDa HBP区分开来。此外,HepG2细胞膜制剂的去糖基化既不影响HDL与95 kDa HBP的结合,也不影响其大小,而相比之下,它会影响HB-2/ALCAM和清道夫受体B-I/CLA-1的分子量。我们得出结论,95 kDa HBP是一种新的HDL受体候选物,在人类细胞和细胞系中广泛表达。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验